Analysts Set Royalty Pharma plc (NASDAQ:RPRX) PT at $41.67

Royalty Pharma plc (NASDAQ:RPRX) has been given an average recommendation of “Moderate Buy” by the six analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $41.67.

RPRX has been the topic of a number of recent analyst reports. Citigroup cut their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. Finally, The Goldman Sachs Group boosted their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $26.66 on Friday. Royalty Pharma has a fifty-two week low of $25.10 and a fifty-two week high of $31.66. The firm’s 50-day simple moving average is $27.15 and its 200 day simple moving average is $27.33. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The stock has a market cap of $15.71 billion, a P/E ratio of 13.81, a P/E/G ratio of 4.67 and a beta of 0.47.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a yield of 3.15%. Royalty Pharma’s dividend payout ratio is currently 43.52%.

Hedge Funds Weigh In On Royalty Pharma

A number of institutional investors have recently bought and sold shares of RPRX. Canada Pension Plan Investment Board increased its stake in Royalty Pharma by 5.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company’s stock worth $28,051,000 after purchasing an additional 45,839 shares in the last quarter. BOKF NA increased its stake in Royalty Pharma by 18.4% in the 1st quarter. BOKF NA now owns 18,280 shares of the biopharmaceutical company’s stock worth $547,000 after purchasing an additional 2,844 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Royalty Pharma in the 1st quarter worth about $487,000. California State Teachers Retirement System increased its stake in Royalty Pharma by 2.1% in the 1st quarter. California State Teachers Retirement System now owns 649,055 shares of the biopharmaceutical company’s stock worth $19,712,000 after purchasing an additional 13,533 shares in the last quarter. Finally, Tidal Investments LLC increased its stake in Royalty Pharma by 28.2% in the 1st quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company’s stock worth $2,740,000 after purchasing an additional 19,834 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.